Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2023-09-01 DOI:10.1016/j.clcc.2023.05.002

Hiroyuki Kodama, Toshiki Masuishi, Munehiro Wakabayashi, Akinobu Nakata, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Kei Muro

{"title":"Differential Efficacy of Targeted Monoclonal Antibodies in Left-Sided Colon and Rectal Metastatic Cancers","authors":"Hiroyuki Kodama, Toshiki Masuishi, Munehiro Wakabayashi, Akinobu Nakata, Ryosuke Kumanishi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Kazunori Honda, Yukiya Narita, Hiroya Taniguchi, Shigenori Kadowaki, Masashi Ando, Kei Muro","doi":"10.1016/j.clcc.2023.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The recommended first-line chemotherapy for <em>RAS/BRAF</em> wild-type metastatic colorectal cancer (mCRC) is bevacizumab (BEV)-containing therapy for right-sided colon cancer (R) and antiepidermal growth factor receptor antibody (anti-EGFR)-containing therapy for left-sided colon cancer (L) or rectal cancer (RE). However, anatomical or biological heterogeneity reportedly exists between L and RE. Therefore, we aimed to compare the efficacies of anti-EGFR and BEV therapies for L and RE, respectively.</p></div><div><h3>Methods</h3><p>We retrospectively reviewed 265 patients with <em>KRAS (RAS</em>)/<em>BRAF</em> wild-type mCRC treated with fluoropyrimidine-based doublet chemotherapy plus anti-EGFR or BEV as the first-line treatment at a single institution. They were divided into 3 groups: R, L, and RE. Overall survival (OS), progression-free survival (PFS), objective response rate, and conversion surgery rate were analyzed.</p></div><div><h3>Results</h3><p>Forty-five patients had R (anti-EGFR/BEV: 6/39), 137 patients had L (45/92), and 83 patients had RE (25/58). In patients with R, both median (m) PFS and OS were superior with BEV therapy (mPFS, anti-EGFR vs. BEV: 8.7 vs. 13.0 months, hazard ratio [HR]: 3.90, <em>P</em> = .01; mOS, 17.1 vs. 33.9 months, HR: 1.54, <em>P</em> = .38). In patients with L, better mPFS and comparable mOS with anti-EGFR therapy were observed (mPFS, 20.0 vs. 13.4 months, HR: 0.68, <em>P</em> = .08; mOS, 44.8 vs. 36.0 months, HR: 0.87, <em>P</em> = .53), whereas, in patients with RE, comparable mPFS and worse mOS with anti-EGFR therapy were observed (mPFS, 17.2 vs. 17.8 months, HR: 1.08, <em>P</em> = .81; mOS, 29.1 vs. 42.2 months, HR: 1.53, <em>P</em> = .17).</p></div><div><h3>Conclusions</h3><p>Efficacies of anti-EGFR and BEV therapies may differ between patients with L and RE.</p></div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002823000361","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 1

Abstract

Background

The recommended first-line chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer (mCRC) is bevacizumab (BEV)-containing therapy for right-sided colon cancer (R) and antiepidermal growth factor receptor antibody (anti-EGFR)-containing therapy for left-sided colon cancer (L) or rectal cancer (RE). However, anatomical or biological heterogeneity reportedly exists between L and RE. Therefore, we aimed to compare the efficacies of anti-EGFR and BEV therapies for L and RE, respectively.

Methods

We retrospectively reviewed 265 patients with KRAS (RAS)/BRAF wild-type mCRC treated with fluoropyrimidine-based doublet chemotherapy plus anti-EGFR or BEV as the first-line treatment at a single institution. They were divided into 3 groups: R, L, and RE. Overall survival (OS), progression-free survival (PFS), objective response rate, and conversion surgery rate were analyzed.

Results

Forty-five patients had R (anti-EGFR/BEV: 6/39), 137 patients had L (45/92), and 83 patients had RE (25/58). In patients with R, both median (m) PFS and OS were superior with BEV therapy (mPFS, anti-EGFR vs. BEV: 8.7 vs. 13.0 months, hazard ratio [HR]: 3.90, P = .01; mOS, 17.1 vs. 33.9 months, HR: 1.54, P = .38). In patients with L, better mPFS and comparable mOS with anti-EGFR therapy were observed (mPFS, 20.0 vs. 13.4 months, HR: 0.68, P = .08; mOS, 44.8 vs. 36.0 months, HR: 0.87, P = .53), whereas, in patients with RE, comparable mPFS and worse mOS with anti-EGFR therapy were observed (mPFS, 17.2 vs. 17.8 months, HR: 1.08, P = .81; mOS, 29.1 vs. 42.2 months, HR: 1.53, P = .17).

Conclusions

Efficacies of anti-EGFR and BEV therapies may differ between patients with L and RE.

查看原文本刊更多论文

靶向单克隆抗体治疗左半结肠癌和直肠转移癌的疗效差异

背景RAS/BRAF野生型转移性癌症（mCRC）的推荐一线化疗是含有贝伐单抗（BEV）的右半结肠癌癌症（R）治疗和含有抗表皮生长因子受体抗体（抗EGFR）的左半结肠癌癌症（L）或癌症（RE）治疗。然而，据报道，L和RE之间存在解剖或生物学异质性。因此，我们旨在比较抗EGFR和BEV疗法分别对L和RE的疗效。方法我们回顾性分析了265例KRAS（RAS）/BRAF野生型mCRC患者，在单一机构接受基于氟嘧啶的双联化疗加抗EGFR或BEV作为一线治疗。他们被分为3组：R组、L组和RE组。分析总生存率（OS）、无进展生存率（PFS）、客观缓解率和转化手术率。结果45例患者有R（抗EGFR/BEV:6/39），137例患者有L（45/92），83例患者有RE（25/58）。在R患者中，BEV治疗的中位（m）PFS和OS均优于BEV治疗（mPFS，抗EGFR与BEV:8.7vs.13.0个月，危险比[HR]:3.90，P=.01；mOS，17.1vs.33.9个月，HR:1.54，P=.38），而在RE患者中，观察到与抗EGFR治疗相当的mPFS和更差的mPOS（mPFS，17.2对17.8个月，HR:1.08，P=.81；mPOS，29.1对42.2个月，HR：1.53，P=.17）。结论L和RE患者的抗EGFR和BEV治疗效果可能不同。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567